查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832351

乳癌液态切片市场（按技术、生物标记类型、应用、样本类型、最终用户和癌症分期）—2025-2032 年全球预测

Breast Cancer Liquid Biopsy Market by Technology, Biomarker Type, Application, Sample Type, End User, Cancer Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年乳癌液态切片市场规模将成长至 25.3499 亿美元，复合年增长率为 19.99%。

主要市场统计数据
基准年2024年 5.8992亿美元
预计2025年 7.0585亿美元
预测年份：2032年 2,534,990,000美元
复合年增长率（%） 19.99%

阐明影响当代乳癌液态切片活检应用和策略重点的技术、临床和商业动态的方向

乳癌液态切片已从前景光明的调查工具发展成为日益实用的传统诊断辅助手段，为肿瘤生物学研究提供了一个微创的窗口。本概述整合了当代科学进展、临床应用模式和商业性动态，为领导者提供简洁可行的指导。液态切片所依赖的技术套件种类繁多，包括高灵敏度的分子检测和广泛的基因组分析方法，以满足从早期检测到復发监测的特定临床需求。

近期的临床研究和监管里程碑凸显了液态切片的价值：识别治疗方法选择中可行的改进措施，监测微量残存疾病以确定是否停止治疗或增加剂量，以及製定监测策略以减少对侵入性组织取样的依赖。同时，样本处理、检测标准化和资讯学方面的创新提高了不同实验室之间结果的可重复性和可解释性。因此，诊断、临床护理和生命科学投资领域的相关人员必须将快速的技术进步与报销、实验室工作流程和临床医生的采用等现实情况相协调。

有鑑于此，执行摘要关注影响相关人员选择的最重要的转变。它强调了对产品开发、临床检验、监管策略和商业模式的实际影响，并指出了近期出现的差异化机会。目标是帮助决策者专注于了解决定液态切片生态系统成功的技术发展轨迹和营运槓桿。

技术进步、多模态生物标记和不断发展的临床工作流程的融合如何迅速重塑乳癌液态切片的实践和商业化

由于技术日趋成熟、临床证据不断累积以及医疗模式向微创诊断方法转变，乳癌液态切片的前景正在改变。检测灵敏度的提高扩大了临床应用范围，使得检测出先前低于可靠阈值的低频突变和微小残留疾病讯号成为可能。这些技术进步为新的临床应用打开了大门，包括復发的纵向监测、晚期和早期疾病的分子引导治疗选择，以及针对高风险族群的标标靶化筛检策略。

同时，多分析物方法和更丰富的生物标记组合的整合，正在推动从单一分析物检测到结合循环肿瘤DNA讯号、循环性肿瘤细胞、外泌体内容物和蛋白质标记的平台转变。正交分析物的整合正在提高临床解读的可靠性，并减少筛检的假阳性。同时，生物资讯学的日益复杂化，包括机器学习主导的讯号反捲积和标准化变异註释，正在减少实验室间的差异，并提高临床效用。

监管和报销生态系统也在发生变化，付款人和指南委员会已经认识到液态切片可以显着改变患者管理的明确用例。诊断开发人员和临床网路之间的合作正在加速前瞻性检验和真实世界证据的产生。综合这些因素，商业性成功不仅取决于检测性能，还取决于生态系统的契合度——实验室整合、临床医生工作流程的协调以及明确的临床效用证据。

评估近期关税变化和贸易政策调整如何改变液态切片生态系统的供应链、筹资策略和营运成本

制定关税政策和跨境贸易措施可能会对支持液态切片解决方案的试剂、设备和组件的供应链造成巨大压力。 2025年，关税调整和贸易相关政策变化将影响进口设备、用于核酸提取和文库製备的耗材以及专用塑胶和微流体组件的成本。这些进口成本的增加将产生连锁效应：实验室营运预算面临每次检测试剂成本的增加，仪器供应商和服务供应商必须重新评估销售定价，采购团队也必须重新审视筹资策略以保护利润。

除了直接成本影响外，关税还可能影响策略采购决策，刺激某些製造活动的近岸外包和供应链多元化。虽然垂直整合的製造商和拥有区域生产基地的公司能够很好地缓衝关税波动，但依赖专业海外供应商的规模较小、创新企业可能面临更长的交货时间和压缩的利润率。为此，各公司正在重新协商供应商合同，增加前置作业时间缓衝，并寻求替代材料和优化工作流程，以保持其检测的成本效益。

重要的是，临床应用和政策相关人员正密切关注成本驱动的检测可得性变化。实验室和医疗保健提供者正在考虑在昂贵的高度自动化平台和低成本的手动工作流程之间进行权衡，尤其是在资金紧张的医疗保健系统中。因此，由关税主导的成本动态正在塑造近期的竞争定位，并促使采购、定价和製造部门采取策略性应对措施。

透过详细的細項分析，将技术类型、生物标记类别、临床应用、样本矩阵、最终用户概况和癌症阶段联繫起来，确定开发路径的优先顺序

对细分市场的细緻理解，揭示了不同的技术路径和临床应用如何创造多种价值路径。技术细分涵盖BEAMing、数位PCR、新一代定序和qPCR平台。数位PCR有晶片式和液滴式两种形式，每种形式都针对不同的通量和灵敏度进行了最佳化。次世代定序仪方法包括专注于可操作热点的靶向panel、扩展转录区覆盖范围以实现发现和广泛分析的全EXOME显子组测序，以及资源密集度更高但能够进行全面基因组分析的全基因组测序。定量PCR平台包括用于同时进行标靶检测的多重定量PCR和用于动态监测应用的即时定量PCR。

生物标记类型的细分涵盖循环游离DNA、循环性肿瘤细胞、循环肿瘤DNA和外泌体，其中外泌体分析分为外泌体蛋白和外泌体RNA评估。循环肿瘤DNA和外泌体RNA对于突变分析和非侵入性分子特征具有重要价值，而循环性肿瘤细胞则提供有助于分析表型和抗药性机制的细胞背景资讯。应用主导的细分区分早期检测、微小残留疾病、復发监测和治疗选择。早期检测本身分为高风险筛检和人群筛检，而微小残留疾病则着重于治疗后监测，需要极高的敏感度和纵向采样保真度。

血清、唾液和尿液样本采集支持分散式采集和以患者为中心的工作流程。最终使用者（诊断实验室、医院和研究机构）的营运优先顺序、监管能力和采购行为决定了其偏好的吞吐量和报告格式。最后，癌症分期通常分为晚期和早期，晚期通常侧重于转移性疾病的应用，其中组织基因分型和治疗决策支持之间的一致性至关重要。综合考虑这些维度，可以根据特定的临床路径和用户需求客製化产品开发和商业化策略，从而最大限度地提高临床影响力和应用率。

不同地区的法规环境、付款人行为和临床网路如何影响液态切片解决方案的采用路径和策略重点

区域动态正在塑造采用曲线和投资重点，从而在关键区域打造差异化的扩展路径。美洲地区的特点是：强大的临床研究活动、成熟的伴随诊断报销途径，以及密集的学术医疗中心网络，能够快速进行前瞻性检验。因此，强调临床效用研究、付款人参与以及与大型实验室网路合作的商业策略在该地区尤其有效。

欧洲、中东和非洲是一个多元化的地区，其监管环境和国家医疗保健体系各不相同，这些因素影响采购决策。在多个欧洲司法管辖区，对临床效用和成本效益的深入评估正在影响技术的应用，鼓励开发者产生真实世界证据和健康经济数据。同时，该地区的一些市场正在投资扩展数位病理学和分子诊断能力，为能够提供适应不同报销系统和检测基础设施的整合解决方案的诊断提供者创造了机会。

亚太地区在某些市场展现出快速的临床应用、政府主导的筛检和早期检测计划以及不断增长的本地製造能力。该地区的一些政策制定者和医疗保健系统正在积极实施可能纳入非侵入性筛检模式的人口健康计划。因此，制定兼顾可扩展性、可负担性以及与当地法规相符的策略，对于在各种医疗保健服务模式中实现更广泛的应用至关重要。

竞争格局洞察凸显了平台创新、证据伙伴关係和服务模式如何决定液态切片领域的领导地位

液态切片领域的竞争是平台创新、策略伙伴关係和生态系统编配的结合。成熟的诊断公司和定序专家持续提升检测灵敏度并拓展可操作性内容，而敏捷的生物技术新兴企业则专注于利基临床应用和独特的生物标誌物，以提供差异化优势。技术提供者和临床网路之间的合作透过加速前瞻性检验研究并将证据产生与临床决策点相结合，支持路径的采用。

仪器和耗材製造商正在推行模组化方法，使实验室能够在保持分析性能的同时逐步扩大产能。同时，以服务为导向的经营模式——集中式参考检测、订阅式分析和实验室即服务——正日益受到青睐，旨在降低临床应用门槛并加快获得结果。投资模式体现了平台主导投资与特定应用型侦测之间的平衡。投资组合多元化可以降低单一用例结果的风险，并增强收益韧性。

此外，整合了强大数据分析、标准化报告和临床医生解读支援工具的公司，更有机会在医院和大型诊断实验室中获得采用。与合约研究组织和学术中心建立策略联盟，有助于进行转化研究，检验临床效用并促进指南的采用。领先企业将卓越的技术与实用的上市模式和循证伙伴关係关係相结合。

为液体活检领域的领导者提供液态切片的优先策略行动，以提高检测性能、稳定供应链、确保报销并加速临床应用

产业领导者应优先考虑一系列策略行动，以协调科学研究能力、营运可扩展性和付款人准备度。首先，重点是投资于符合特定临床用例的检测灵敏度和特异性，特别是那些分析性能直接影响临床决策的用例，例如微小残留疾病和高风险族群的早期检测。将前瞻性临床试验融入治疗路径，以补充技术开发，证明对治疗选择和患者预后有实际的影响。

其次，我们将透过多元化零件采购和评估本地製造和组装方案来增强供应链的韧性。这些措施将减少贸易相关成本波动所带来的风险，并缩短临床实验室的部署时间。第三，我们将设计反映最终使用者工作流程的商业模式。这些模式包括为诊断实验室提供灵活的实验室集成，为医院系统提供承包解决方案，以及建立研究伙伴关係，以降低学术中心采用的技术门槛。我们将投资于临床医生的解读工具和报告标准，以减轻认知负担并简化部署。

第四，我们正在与付款方和卫生技术评估机构建立早期合作关係，以整合可靠的真实世界证据和符合区域报销框架的卫生经济数据。第五，我们正在寻求跨诊断、製药和临床研究生态系统的伙伴关係，将检测方法纳入治疗开发项目和指南制定研究。最后，我们坚持严谨的投资组合策略，在平台投资和标靶检测方法之间取得平衡，从而既能提供广泛的能力，又能在重点临床领域实现差异化。

透明的研究框架，结合系统性的文献综述和相关人员访谈，提供检验的、基于本地的策略见解

本分析所采用的研究途径将结构化的二手文献整合与主要相关人员访谈相结合，以确保研究结果反映当前的科学、监管和商业性现状。二手文献研究包括对同行评审的临床研究、监管指南文件、会议论文集和开放原始码技术白皮书的系统综述，以及对检测性能特征、生物标记检验和不断发展的临床指南的分析。已发表的分析灵敏度和特异性基准进行了交叉检验，重点是理解当代生物资讯学在变异调用和解读方面的实践。

初步研究包括对临床肿瘤学家、实验室主任、付款方和行业高管的深入访谈，旨在识别应用障碍、采购重点和证据预期。访谈样本来自不同地区，旨在捕捉监管解读和医疗服务提供模式的地区差异。数据和见解透过跨资讯来源三角测量，以减轻单一资讯来源的偏见，并协调对照研究结果与实际营运限制之间的差异。

我们的分析方法包括定性主题分析（旨在提取策略意义）和情境评估（旨在评估政策变化下的供应链和定价敏感度）。我们承认研究有其限制；因此，建议持续监测已发表的科学文献和监管动态。在整个研究过程中，我们遵守伦理研究规范，包括知情同意和专有资讯保密。

关于协调分析创新、证据生成和商业性实施以实现液态切片在乳癌治疗中的临床前景的总结性观点

乳癌液态切片正处于曲折点，技术能力、临床需求和商业性奖励正在相互协调，以实现更广泛的临床效用。高灵敏度检测和多参数方法的成熟，使得非侵入性检测在治疗选择、微量残存疾病监测和分层筛检策略中发挥重要作用成为可能。同时，供应链可靠性、报销协调和实验室营运整合等实际限制因素将决定其应用的速度和规模。

为了抓住这一机会，各机构必须采取整合策略，将强大的分析能力与符合临床决策点和付款人期望的证据生成相结合。在临床医生教育、报告标准化以及将检测方法纳入治疗开发项目的伙伴关係方面的投资，将加速该技术的采用。由于法律规范、报销机制和医疗保健服务模式等区域差异，需要采取针对特定地区的方案，而非一刀切的商业化计划。

最终，液态切片的临床前景将透过协调一致的行动得以实现：审慎的技术开发、可控的证据生成，以及适应不断变化的政策和医疗服务环境的商业策略。迅速采取行动协调这些要素的相关人员将最有能力塑造医疗标准，并获得长期的临床和商业性价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 超灵敏甲基化 ctDNA 检测的进展提高了乳癌微量残存疾病的检测率
  • 扩大照护现场液态生物检体平台，快速监测转移性乳癌的治疗反应
  • 製药和诊断公司合作开发用于标靶治疗的伴随液态生物检体测试
  • 基于外泌体的液态生物检体测试的出现提供了全面的生物标记分析和对抗药性的洞察
  • 突破性乳癌液态切片检测获得FDA核准监管批准，加速其商业性应用
  • 开发标准化的预分析工作流程，以减少样本采集和 ctDNA 分析的差异
  • 扩大报销范围和支持在临床实践中常规使用液态生物检体的卫生经济证据
  • 透过整合ctDNA、外泌体RNA和蛋白质标记物的多组体学方法进行全面的疾病监测

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章乳癌液态切片市场（按技术）

  • 喜气洋洋
  • 数位PCR
    • 基于晶片的数位PCR
    • 液滴式数位PCR
  • 下一代定序
    • 目标序列
    • 全EXOME定序
    • 全基因组序列分析
  • 定量PCR
    • 多重定量PCR
    • 实时定量PCR

第九章乳癌液态切片市场（按生物标记类型）

  • 循环游离DNA
  • 循环性肿瘤细胞
  • 循环肿瘤DNA
  • 外泌体
    • 外泌体蛋白
    • 外泌体RNA

第 10 章乳癌液态切片市场（按应用）

  • 早期检测
    • 高风险筛检
    • 人口筛检
  • 微量残存疾病
    • 治疗后监测
  • 復发监测
  • 治疗方案

第 11 章乳癌液态切片市场（依样本类型）

  • 电浆
  • 唾液
  • 血清
  • 尿

第 12 章乳癌液态切片市场（按最终用户）

  • 诊断实验室
  • 医院
  • 研究所

第十三章乳癌液态切片市场（按癌症分期）

  • 晚期
    • 转移性疾病
  • 早期的

第十四章乳癌液态切片市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章乳癌液态切片市场：按类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章乳癌液态切片市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Roche Diagnostics International AG
    • Guardant Health, Inc.
    • Natera, Inc.
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Exact Sciences Corporation
    • Sysmex Inostics GmbH
    • Qiagen NV
    • Bio-Rad Laboratories, Inc.
    • Biocept, Inc.
Product Code: MRR-437D45958552

The Breast Cancer Liquid Biopsy Market is projected to grow by USD 2,534.99 million at a CAGR of 19.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 589.92 million
Estimated Year [2025] USD 705.85 million
Forecast Year [2032] USD 2,534.99 million
CAGR (%) 19.99%

A clear orientation to the technological, clinical, and commercial dynamics that define contemporary breast cancer liquid biopsy adoption and strategic priorities

Liquid biopsy for breast cancer has evolved from a promising research tool into an increasingly practical adjunct to conventional diagnostics, offering a minimally invasive window into tumor biology. This summary synthesizes contemporary scientific advances, clinical adoption patterns, and commercial dynamics to provide leaders with a concise, actionable orientation. The technology suite underpinning liquid biopsy is diverse, spanning highly sensitive molecular assays and broad genomic profiling approaches that address distinct clinical needs from early detection to recurrence monitoring.

Recent clinical studies and regulatory milestones have clarified where liquid biopsy adds value: in identifying actionable alterations for therapy selection, monitoring minimal residual disease to support treatment de-escalation or escalation decisions, and enabling surveillance strategies that reduce reliance on more invasive tissue sampling. Simultaneously, innovation in sample handling, assay standardization, and informatics has improved reproducibility and interpretability of results across laboratories. As a result, stakeholders across diagnostics, clinical care, and life sciences investment must reconcile rapid technical progress with the realities of reimbursement, laboratory workflows, and clinician adoption.

Given this context, the executive summary foregrounds the most consequential shifts shaping stakeholders' choices. It emphasizes practical implications for product development, clinical validation, regulatory strategy, and commercial models, and it identifies where near-term opportunities for differentiation are emerging. The aim is to equip decision-makers with a focused understanding of technology trajectories and operational levers that will determine success in the liquid biopsy ecosystem.

How converging technical advances, multimodal biomarkers, and evolving clinical workflows are rapidly reshaping breast cancer liquid biopsy practice and commercialization

The landscape of breast cancer liquid biopsy is being transformed by a confluence of technical maturation, clinical evidence accumulation, and shifting care paradigms that favor less invasive diagnostics. Advances in assay sensitivity have expanded the clinical envelope, enabling detection of low-frequency variants and minimal residual disease signals that were previously below reliable thresholds. This technical progress has, in turn, unlocked new clinical applications: longitudinal monitoring for recurrence, molecularly informed treatment selection in both advanced and earlier stages, and targeted screening strategies for high-risk cohorts.

Concurrently, integration of multi-analyte approaches and richer biomarker panels is fostering a move away from single-analyte assays toward platforms that combine circulating tumor DNA signals with circulating tumor cells, exosomal content, and protein markers. The integration of orthogonal analytes improves confidence in clinical interpretation and reduces false positives in screening contexts. In parallel, the growing sophistication of bioinformatics, including machine learning-driven signal deconvolution and standardized variant annotation, is reducing inter-laboratory variability and improving clinical utility.

Regulatory and reimbursement ecosystems are also shifting, with payers and guideline committees increasingly recognizing defined use cases where liquid biopsy meaningfully alters patient management. Partnerships between diagnostic developers and clinical networks are accelerating prospective validation and real-world evidence generation. Taken together, these forces create a landscape in which commercial success depends not only on assay performance but on ecosystem fit-laboratory integration, clinician workflow alignment, and clear evidence of clinical benefit.

Assessment of how recent tariff shifts and trade policy adjustments are altering supply chains, procurement strategies, and operational costs in the liquid biopsy ecosystem

Tariff policy developments and cross-border trade measures can exert meaningful pressure on the supply chain for reagents, instruments, and components that underpin liquid biopsy solutions. In 2025, tariff adjustments and trade-related policy shifts have affected costs for imported instrumentation, consumables used in nucleic acid extraction and library preparation, and specialized plastics and microfluidic components. These added import costs have a cascading effect: laboratory operating budgets face higher per-test reagent expenses; instrument vendors and service providers reassess distribution pricing; and procurement teams must re-evaluate sourcing strategies to protect margins.

Beyond direct cost impacts, tariffs influence strategic sourcing decisions and may spur nearshoring of certain manufacturing activities or supply chain diversification. Companies with vertically integrated manufacturing or regional production footprints are better positioned to buffer tariff volatility, while smaller innovators reliant on specialized overseas suppliers may face longer lead times and margin compression. In response, firms are renegotiating supplier contracts, increasing inventory buffers, and pursuing alternative materials or workflow optimizations to maintain assay cost-effectiveness.

Importantly, clinical adoption and policy stakeholders are attentive to any cost-driven shifts in test accessibility. Laboratories and healthcare providers weigh the trade-offs between premium, highly automated platforms and lower-cost manual workflows, especially in health systems under fiscal pressure. Thus, tariff-driven cost dynamics are shaping near-term competitive positioning and prompting strategic responses across procurement, pricing, and manufacturing that will influence which technologies scale and where clinical services expand.

In-depth segmentation analysis that links technology types, biomarker classes, clinical applications, sample matrices, end user profiles, and cancer stage to prioritize development pathways

A nuanced understanding of segmentation reveals how distinct technological pathways and clinical applications create multiple routes to value. Technology segmentation spans BEAMing, digital PCR, next generation sequencing, and qPCR platforms. Within digital PCR there are chip-based and droplet implementations, each optimized for different throughput and sensitivity trade-offs. Next generation sequencing approaches include targeted panels that concentrate on actionable hotspots, whole exome sequencing that expands coverage of coding regions for discovery and broader profiling, and whole genome sequencing that, while more resource-intensive, enables comprehensive genomic interrogation. Quantitative PCR platforms include multiplex quantitative PCR for simultaneous target detection and real-time quantitative PCR for dynamic monitoring applications.

Biomarker type segmentation captures circulating free DNA, circulating tumor cells, circulating tumor DNA, and exosomes, with exosomal analyses split into exosomal protein and exosomal RNA assessments. These analyte distinctions matter clinically: circulating tumor DNA and exosomal RNA are valuable for mutation profiling and non-invasive molecular signatures, while circulating tumor cells provide cellular context that can inform phenotypic and resistance mechanism analyses. Application-driven segmentation differentiates early detection, minimal residual disease, recurrence monitoring, and treatment selection. Early detection itself bifurcates into high-risk screening and population screening, while minimal residual disease focuses on post-treatment surveillance, requiring exceptionally high sensitivity and longitudinal sampling fidelity.

Sample type further conditions assay design and logistics; plasma remains the dominant matrix for DNA-based assays, while serum, saliva, and urine open opportunities for decentralized collection and patient-centric workflows. End users-diagnostic laboratories, hospitals, and research institutes-have distinct operational priorities, regulatory competencies, and purchasing behaviors that determine preferred throughput and reporting formats. Finally, cancer stage segmentation separates advanced stage and early stage disease, with the advanced stage often emphasizing metastatic-disease applications where concordance with tissue genotyping and therapeutic decision support is critical. When these dimensions are considered together, product development and commercialization strategies can be tailored to specific clinical pathways and user needs to maximize clinical impact and adoption.

How distinct regulatory environments, payer behaviors, and clinical networks across major regions are directing adoption pathways and strategic priorities for liquid biopsy solutions

Regional dynamics shape adoption curves and investment priorities, producing differentiated pathways to scale across major geographies. The Americas are characterized by robust clinical research activity, established reimbursement pathways for defined companion diagnostics, and a dense network of academic medical centers enabling rapid prospective validation. As a result, commercial strategies that emphasize clinical utility studies, payer engagement, and partnerships with large laboratory networks are particularly effective in this region.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks vary and national healthcare systems drive procurement decisions. In several European jurisdictions, centralized assessment of clinical utility and cost-effectiveness influences adoption, encouraging developers to generate real-world evidence and health economic data. Meanwhile, certain markets within this region are investing in digital pathology and molecular diagnostics capacity expansion, creating opportunities for diagnostic providers that can offer integrated solutions adaptable to diverse reimbursement and laboratory infrastructures.

Asia-Pacific demonstrates a combination of rapid clinical adoption in select markets, government-led screening and early detection initiatives, and growing local manufacturing capabilities. Policymakers and healthcare systems in parts of this region are actively implementing population health programs that could incorporate non-invasive screening paradigms. Consequently, strategies that address scalability, affordability, and local regulatory alignment are essential to realize broader uptake across varied healthcare delivery models.

Competitive landscape insights highlighting how platform innovation, evidence partnerships, and service models are determining leadership in the liquid biopsy arena

Competitive activity in the liquid biopsy domain combines platform innovation, strategic partnerships, and ecosystem orchestration. Established diagnostic firms and sequencing specialists continue to refine assay sensitivity and broaden actionable content, while nimble biotech startups focus on niche clinical applications or proprietary biomarkers that promise differentiation. Collaborative arrangements between technology providers and clinical networks accelerate prospective validation studies and support pathway adoption by aligning evidence generation with clinical decision points.

Manufacturers of instrumentation and consumables are pursuing modular approaches that allow laboratories to scale capacity incrementally while preserving analytical performance. At the same time, service-oriented business models-centralized reference testing, subscription analytics, and laboratory-as-a-service offerings-are gaining traction as ways to lower barriers to clinical use and accelerate time to result. Investment patterns reflect a balance between platform-led bets and application-specific assays; portfolio diversification reduces exposure to single-use-case outcomes and supports revenue resilience.

Additionally, companies that integrate robust data analytics, standardized reporting, and clinician-facing interpretive support tools are better positioned to win adoption among hospitals and large diagnostic laboratories. Strategic alliances with contract research organizations and academic centers facilitate translational studies that validate clinical utility and foster guideline inclusion, which in turn strengthens long-term commercial prospects. Leaders will be those that couple technical excellence with pragmatic go-to-market models and evidence-generating partnerships.

Practical and prioritized strategic actions for leaders to enhance assay performance, stabilize supply chains, secure reimbursement, and accelerate clinical adoption in liquid biopsy

Industry leaders should prioritize a set of strategic moves that align scientific capability with operational scalability and payer readiness. First, focus investment on assay sensitivity and specificity that match defined clinical use cases, especially minimal residual disease and early detection in high-risk cohorts, where analytical performance directly influences clinical decision-making. Complement technical development with prospective clinical studies embedded in care pathways to demonstrate actionable impact on treatment choices and patient outcomes.

Second, strengthen supply chain resilience by diversifying component sourcing and evaluating regional manufacturing or assembly options. Such measures reduce exposure to trade-related cost volatility and improve time-to-deployment for clinical sites. Third, design commercial models that reflect end-user workflows: offer flexible laboratory integrations for diagnostic laboratories, turn-key solutions for hospital systems, and research partnerships that lower technical adoption barriers for academic centers. Invest in clinician-facing interpretive tools and reporting standards to reduce cognitive burden and streamline uptake.

Fourth, cultivate payer and health technology assessment engagement early, providing robust real-world evidence and health economic data tailored to regional reimbursement frameworks. Fifth, pursue partnerships across the diagnostic, pharma, and clinical research ecosystem to embed assays in therapeutic development programs and guideline-forming studies. Finally, maintain a disciplined portfolio approach that balances platform investments with targeted assays, enabling both broad capability and focused differentiation in priority clinical niches.

A transparent research framework combining systematic literature review and targeted stakeholder interviews to produce validated, regionally aware strategic insights

The research approach underpinning this analysis combined structured secondary literature synthesis with targeted primary stakeholder engagement to ensure findings reflect current scientific, regulatory, and commercial realities. Secondary research involved systematic review of peer-reviewed clinical studies, regulatory guidance documents, conference proceedings, and open-source technical white papers to map assay performance characteristics, biomarker validation, and evolving clinical guidelines. Emphasis was placed on cross-validating published analytic sensitivity and specificity benchmarks and on understanding contemporary bioinformatics practices for variant calling and interpretation.

Primary research included in-depth interviews with clinical oncologists, laboratory directors, payers, and industry executives to contextualize barriers to adoption, procurement priorities, and evidence expectations. Interviews were conducted with a geographically diverse sample to capture regional differences in regulatory interpretation and healthcare delivery models. Data and insights were triangulated across sources to mitigate single-source bias and to reconcile differences between controlled study outcomes and real-world operational constraints.

Analytical methods included qualitative thematic analysis to distill strategic implications and scenario-based assessment to evaluate supply chain and pricing sensitivities under policy shifts. Limitations are acknowledged: rapidly emerging studies and proprietary commercial developments can change the competitive landscape; therefore, continuous surveillance of scientific literature and regulatory announcements is recommended. Ethical research practices, including informed consent for interviews and confidentiality safeguards for proprietary inputs, were observed throughout the process.

Concluding perspective on aligning analytical innovation, evidence generation, and commercial execution to realize the clinical promise of liquid biopsy in breast cancer care

Liquid biopsy for breast cancer stands at an inflection point where technical capability, clinical need, and commercial incentive are aligning to enable broader clinical utility. The maturation of high-sensitivity assays and multi-analyte approaches increases the likelihood that non-invasive tests will play a substantive role in treatment selection, minimal residual disease monitoring, and stratified screening strategies. At the same time, pragmatic constraints such as supply chain reliability, reimbursement alignment, and laboratory operational integration will determine the pace and scale of adoption.

To capitalize on this moment, organizations must adopt integrated strategies that pair robust analytical performance with evidence generation tailored to clinical decision points and payer expectations. Investment in clinician education, standardization of reporting, and partnerships that embed assays within therapeutic development programs will accelerate acceptance. Regional nuances-differences in regulatory frameworks, reimbursement mechanisms, and healthcare delivery models-require localized approaches rather than one-size-fits-all commercialization plans.

Ultimately, the clinical promise of liquid biopsy will be realized through coordinated action: deliberate technical development, disciplined evidence generation, and adaptive commercial strategies that respond to evolving policy and care delivery landscapes. Stakeholders that move quickly to align these elements will shape the standards of care and capture long-term clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in ultra-sensitive methylation-based ctDNA assays improving minimal residual disease detection in breast cancer
  • 5.2. Expansion of point-of-care liquid biopsy platforms for rapid monitoring of therapy response in metastatic breast cancer
  • 5.3. Collaboration between pharmaceutical and diagnostics companies to co-develop companion liquid biopsy tests for targeted therapies
  • 5.4. Emergence of exosome-based liquid biopsy tests offering comprehensive biomarker profiling and drug resistance insights
  • 5.5. Regulatory approvals of FDA-designated breakthrough breast cancer liquid biopsy tests accelerating commercial adoption
  • 5.6. Development of standardized preanalytical workflows to reduce variability in sample collection and ctDNA analysis
  • 5.7. Increasing reimbursement coverage and health economic evidence supporting routine liquid biopsy use in clinical practice
  • 5.8. Integration of multi-omics approaches combining ctDNA, exosome RNA, and protein markers for holistic disease monitoring

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Market, by Technology

  • 8.1. BEAMing
  • 8.2. Digital PCR
    • 8.2.1. Chip Based Digital PCR
    • 8.2.2. Droplet Digital PCR
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. qPCR
    • 8.4.1. Multiplex Quantitative PCR
    • 8.4.2. Real Time Quantitative PCR

9. Breast Cancer Liquid Biopsy Market, by Biomarker Type

  • 9.1. Circulating Free DNA
  • 9.2. Circulating Tumor Cells
  • 9.3. Circulating Tumor DNA
  • 9.4. Exosomes
    • 9.4.1. Exosomal Protein
    • 9.4.2. Exosomal RNA

10. Breast Cancer Liquid Biopsy Market, by Application

  • 10.1. Early Detection
    • 10.1.1. High Risk Screening
    • 10.1.2. Population Screening
  • 10.2. Minimal Residual Disease
    • 10.2.1. Post Treatment Surveillance
  • 10.3. Recurrence Monitoring
  • 10.4. Treatment Selection

11. Breast Cancer Liquid Biopsy Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Saliva
  • 11.3. Serum
  • 11.4. Urine

12. Breast Cancer Liquid Biopsy Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Breast Cancer Liquid Biopsy Market, by Cancer Stage

  • 13.1. Advanced Stage
    • 13.1.1. Metastatic Disease
  • 13.2. Early Stage

14. Breast Cancer Liquid Biopsy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Cancer Liquid Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Cancer Liquid Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Diagnostics International AG
    • 17.3.2. Guardant Health, Inc.
    • 17.3.3. Natera, Inc.
    • 17.3.4. Illumina, Inc.
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. Exact Sciences Corporation
    • 17.3.7. Sysmex Inostics GmbH
    • 17.3.8. Qiagen N.V.
    • 17.3.9. Bio-Rad Laboratories, Inc.
    • 17.3.10. Biocept, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-20